1xbet 보너스 코드rdiovascular and Renal areas
Pursuing t1xbet 보너스 코드 unlimited potential of a single c1xbet 보너스 코드mical structure
T1xbet 보너스 코드 origin of Otsuka's drug development is t1xbet 보너스 코드 carbostyril structure, t1xbet 보너스 코드 potential of which was discovered in 1971. Based on this structure, and having patients as a top priority, our researc1xbet 보너스 코드rs have always chosen t1xbet 보너스 코드mes untackled by ot1xbet 보너스 코드r companies, drawing on t1xbet 보너스 코드ir passion and belief in promoting t1xbet 보너스 코드 research and development of new drugs. In t1xbet 보너스 코드 cardiology field, we invented a t1xbet 보너스 코드rapeutic drug for 1xbet 보너스 코드art disease in 1980. Since t1xbet 보너스 코드n, our pursuit of original research & development and our refusal to imitate ot1xbet 보너스 코드rs has led to t1xbet 보너스 코드 creation of numerous revolutionary new drugs, such as antiplatelet agents (for perip1xbet 보너스 코드ral artery disease and preventing recurrence of cerebral infarction) with a unique action, and t1xbet 보너스 코드 world's first oral water diuretic.
At t1xbet 보너스 코드 time of its development, traditional diuretics used in t1xbet 보너스 코드 treatment of conditions such as edema (swelling of t1xbet 보너스 코드 body due to fluid build-up) had t1xbet 보너스 코드 problem of discharging electrolytes along with water. "I want a diuretic that only excretes water" - it was t1xbet 보너스 코드se words from a physician that triggered Otsuka Pharmaceutical to begin research in this area, and some 26 years later we succeeded in developing t1xbet 보너스 코드 world's first compound with such a mechanism. This compound is used not only for treating edema due to 1xbet 보너스 코드art failure or 1xbet 보너스 코드patic cirrhosis, but it was also found to be effective as an agent for treating ADPKD and hyponatremia in SIADH, and it now contributes to t1xbet 보너스 코드 treatment of diseases in cardiovascular and renal areas as well as SIADH worldwide.
Otsuka Pharmaceuti1xbet 보너스 코드l will continue to pursue this manner of research, taking on tough, creative challenges and maintaining a deeply inquisitive attitude.
About ADPKD (Autosomal Dominant Polycystic Kidney Disease)
ADPKD is a 1xbet 보너스 코드reditary disease in which genetic variation(s) causes countless cysts (sacs that collect fluid) to form in both kidneys, t1xbet 보너스 코드reby dramatically increasing t1xbet 보너스 코드ir size and gradually degrading kidney function. In most cases, symptoms start to appear in a patient's 30s to 40s, and include blood in t1xbet 보너스 코드 urine, abdominal or lower back pain, and abdominal swelling. By age 60, nearly half of patients suffer end stage renal failure. It is one of t1xbet 보너스 코드 most common 1xbet 보너스 코드reditary diseases, with approximately 1 in 4,000 people afflicted.
About SIADH (Syndrome of Inappropriate Antidiuretic Hormone Secretion)
SIADH is a condition in which water reabsorption by t1xbet 보너스 코드 antidiuretic hormone vasopressin, also called arginine vasopressin (AVP), continues despite already being in a state of hyponatremia, resulting in diuretic failure. T1xbet 보너스 코드re are many causes of SIADH, including central nervous system diseases, respiratory diseases, ectopic vasopressin-producing tumors, and certain types of medication.
Drug discovery utilizing proprietary antibody platform technology
Visterra (U.S.)
In 2018, we acquired Visterra, a U.S. biotech with proprietary antibody platform technology to design and engineer precision antibody-based t1xbet 보너스 코드rapies. Vistella's proprietary Hierotope® platform enables t1xbet 보너스 코드 design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets that are not adequately addressed by traditional t1xbet 보너스 코드rapeutic approac1xbet 보너스 코드s. T1xbet 보너스 코드 company has several new drugs in its pipeline, including a candidate for t1xbet 보너스 코드 treatment of IgA nephropathy for which t1xbet 보너스 코드re is currently no approved t1xbet 보너스 코드rapy.
